TESARO,Inc. (NASDAQ:TSRO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

TESARO,Inc. (NASDAQ:TSRO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On October23, 2017, Edward C. English submitted his resignation as principal accounting officer of TESARO,Inc. (the “Company”), in order to pursue personal interests after serving with the company since 2012. Mr.English will continue to serve until the effective date of his resignation on November24, 2017. It is expected that Timothy Pearson, the Company’s Executive Vice President and Chief Financial Officer, will serve as the Company’s principal accounting officer until a successor is appointed. Mr.English’s departure is not due to a dispute or disagreement with the Company or its independent accountants.

Section7 – Regulation FD

Item 7.01. Regulation FD Disclosure.

On October25, 2017, the Company issued a press release announcing that the U.S. Food and Drug Administration has approved the Company’s new drug application for the intravenous formulation of VARUBI® (rolapitant) in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.

A copy of the press release is furnished as Exhibit99.1 to this Current Report on Form8-K.

Section9 – Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits


TESARO, Inc. Exhibit
EX-99.1 2 a17-24535_1ex99d1.htm EX-99.1 Exhibit 99.1     TESARO ANNOUNCES U.S. FDA APPROVAL OF VARUBI® IV FOR DELAYED NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY   ·                  VARUBI injectable emulsion features a ready-to-use,…
To view the full exhibit click here

About TESARO,Inc. (NASDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform. It offers VARUBI (rolapitant), which is an oral substance P/neurokinin 1 (NK-1) receptor antagonist for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It is developing IV formulation of rolapitant, which has completed various Phase 1 clinical trials. Its niraparib is an orally active and poly (ADP-ribose) polymerase (PARP) inhibitor. Its immuno-oncology platform has immuno-oncology programs, which include TSR-022 and TSR-042.